M&A Deal Summary |
|
---|---|
Date | 2016-07-11 |
Target | Sagent Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Nichi-Iko Pharmaceutical |
Deal Type | Add-on Acquisition |
Deal Value | 736M USD |
Advisor(s) | Perella Weinberg Partners Morgan Stanley (Financial) Kirkland & Ellis (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1965 |
Sector | Medical Products |
Employees | 2,725 |
Revenue | 179.1B JPY (2022) |
Nichi-Iko Pharmaceutical is a generic drug manufacturer. It has grown market share with an extensive lineup of more than 1,000 commercialized products. Nichi-Iko Pharmaceutical was founded in 1965 and is based in Toyama, Japan.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (Illinois) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2016) | 1 of 1 |
Size (of disclosed) | 1 of 1 |